Climb Bio (CLYM) Short Interest Ratio & Short Volume

Short interest is the volume of Climb Bio shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 919,400 shares of CLYM short. 1.72% of Climb Bio's shares are currently sold short. Learn More on Climb Bio's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLYM shares currently have a short interest ratio of 2.0. Learn More on Climb Bio's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.72% of Climb Bio's floating shares are currently sold short.

Climb Bio saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 919,400 shares, an increase of 4.6% from the previous total of 879,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Climb Bio currently has issued a total of 67,760,000 shares. Some of Climb Bio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Climb Bio currently has a public float of 53,400,000 shares.

1.72% of Climb Bio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Climb Bio: Inhibrx Biosciences, Inc. (5.32%), CytomX Therapeutics, Inc. (19.02%), Organogenesis (18.20%), Gossamer Bio, Inc. (12.05%), CryoPort, Inc. (5.84%), Monopar Therapeutics Inc. (3.54%), Cullinan Therapeutics, Inc. (16.81%), Fulcrum Therapeutics, Inc. (6.19%), Eton Pharmaceuticals, Inc. (14.75%), DBV Technologies S.A. (0.09%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($15.71 billion), Robinhood Markets, Inc. ($7.56 billion), Reddit Inc. ($4.55 billion), Coinbase Global, Inc. ($4.53 billion), CoreWeave Inc. ($4.43 billion), Charter Communications, Inc. ($4.07 billion), Seagate Technology Holdings PLC ($3.94 billion), IonQ, Inc. ($3.78 billion), TC Energy Corporation ($3.13 billion), and Live Nation Entertainment, Inc. ($3.12 billion). View all of the most shorted stocks.

Short selling CLYM is an investing strategy that aims to generate trading profit from Climb Bio as its price is falling. CLYM shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Climb Bio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLYM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLYM, twice per month. The most recent reporting period available is September, 30 2025.